VIR-7831 for the Early Treatment of COVID-19 in Outpatients (COMET-ICE)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04545060 |
|
Recruitment Status :
Active, not recruiting
First Posted : September 10, 2020
Last Update Posted : August 19, 2021
|
Sponsor:
Vir Biotechnology, Inc.
Collaborator:
GlaxoSmithKline
Information provided by (Responsible Party):
Vir Biotechnology, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This is a phase 2/3 study in which subjects with coronavirus disease 2019 (COVID-19) will receive VIR-7831 or placebo and will be assessed for safety, tolerability, efficacy, and pharmacokinetics.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Covid19 | Biological: VIR-7831 Drug: Placebo | Phase 2 Phase 3 |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 1360 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | A Randomized, Multi-center, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Monoclonal Antibody VIR-7831 for the Early Treatment of Coronavirus Disease 2019 (COVID-19) in Non-hospitalized Patients |
| Actual Study Start Date : | August 27, 2020 |
| Actual Primary Completion Date : | April 8, 2021 |
| Estimated Study Completion Date : | August 2021 |
| Arm | Intervention/treatment |
|---|---|
| Experimental: VIR-7831 |
Biological: VIR-7831
VIR-7831 given by intravenous infusion |
| Placebo Comparator: Placebo |
Drug: Placebo
Sterile normal saline (0.9% NaCl) given by intravenous infusion |
Primary Outcome Measures :
- Proportion of participants who have progression of COVID-19 through Day 29 [ Time Frame: Up to Day 29 ]
Secondary Outcome Measures :
- Occurence of of adverse events (AEs) [ Time Frame: Up to 24 weeks ]
- Occurrence of serious adverse events (SAEs) [ Time Frame: Up to 24 weeks ]
- Occurrence of adverse events of special interest (AESI) [ Time Frame: Up to 24 weeks ]
- Incidence and titers (if applicable) of serum ADA to VIR-7831 [ Time Frame: Up to 24 weeks ]
- Cmax [ Time Frame: Up to 24 weeks ]
- Clast [ Time Frame: Up to 24 weeks ]
- Tmax [ Time Frame: Up to 24 weeks ]
- Tlast [ Time Frame: Up to 24 weeks ]
- AUCinf [ Time Frame: Up to 24 weeks ]
- AUClast [ Time Frame: Up to 24 weeks ]
- %AUCextrap [ Time Frame: Up to 24 weeks ]
- t1/2 [ Time Frame: Up to 24 weeks ]
- Vz [ Time Frame: Up to 24 weeks ]
- Vss [ Time Frame: Up to 24 weeks ]
- CL [ Time Frame: Up to 24 weeks ]
- Proportion of participants who have progression of COVID-19 through Day 29 as defined by visit to a hospital emergency room for management or illness, or hospitalization for acute management of illness or death [ Time Frame: Up to Day 29 ]
- Mean change in FLU PRO Plus total score comparing Vir 7831 vs Placebo (AUC through Day 7) and time to symptom alleviation using the FLU-Pro Plus [ Time Frame: Up to Day 7 ]
- Change from baseline in viral load in nasal secretions by qRT-PCR at Day 8 [ Time Frame: Up to Day 8 ]
- Proportion of participants who progress to develop severe and/or critical respiratory COVID-19 as manifest by requirement for and method of supplemental oxygen at Day 8, Day 15, Day 22 or Day 29 [ Time Frame: Up to Day 29 ]
- 29-day, 60-day, and 90-day all-cause mortality [ Time Frame: Up to 90 days ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Participant must be aged 18 years or older AND at high risk of progression of COVID-19 or ≥ 55 years old
- Participants must have a positive SARS-CoV-2 test result and oxygen saturation ≥94% on room air and have COVID-19 symptoms and be less than or equal to 5 days from onset of symptoms
Exclusion Criteria:
- Currently hospitalized or judged by the investigator as likely to require hospitalization in the next 24 hours
- Symptoms consistent with severe COVID-19
- Participants who, in the judgement of the investigator are likely to die in the next 7 days
- Severely immunocompromised participants
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04545060
Locations
Show 91 study locations
Sponsors and Collaborators
Vir Biotechnology, Inc.
GlaxoSmithKline
| Responsible Party: | Vir Biotechnology, Inc. |
| ClinicalTrials.gov Identifier: | NCT04545060 |
| Other Study ID Numbers: |
VIR-7831-5001 GSK Study 214367 ( Other Identifier: GlaxoSmithKline ) |
| First Posted: | September 10, 2020 Key Record Dates |
| Last Update Posted: | August 19, 2021 |
| Last Verified: | August 2021 |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Vir Biotechnology, Inc.:
|
SARS-CoV-2 coronavirus coronavirus disease 2019 COVID-19 |